The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.

On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.

Click here to watch the episode.